MindWalk (HYFT) versus Its Rivals Head-To-Head Contrast

MindWalk (NASDAQ:HYFT) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its competitors? We will compare MindWalk to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk.

Risk and Volatility

MindWalk has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, MindWalk’s competitors have a beta of 5.76, indicating that their average stock price is 476% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for MindWalk and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	0	0	1.50
MindWalk Competitors	4899	9970	16004	378	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 66.78%. Given MindWalk’s competitors stronger consensus rating and higher probable upside, analysts clearly believe MindWalk has less favorable growth aspects than its competitors.

Profitability

This table compares MindWalk and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-145.58%	-56.75%	-31.55%
MindWalk Competitors	-2,662.44%	-364.10%	-42.99%

Valuation & Earnings

This table compares MindWalk and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$17.59 million	-$21.69 million	-1.83
MindWalk Competitors	$432.23 million	-$67.62 million	-10.60

MindWalk’s competitors have higher revenue, but lower earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MindWalk competitors beat MindWalk on 8 of the 13 factors compared.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.